Researchers at the University of Geneva, together with colleagues at CHUV and UNIL, have visualised the exact moment a human T cell engages a tumour cell. Using a method called cryo‑expansion microscopy, they captured a three‑dimensional, nanometre‑scale view of the “dome” that forms at the interface of the two cells. The dome‑shaped membrane region is the site where the T cell releases cytotoxic granules directly onto the cancer cell, initiating cell death.
The technique works by rapidly freezing freshly obtained tumour samples, preserving them in a near‑native state. The frozen tissue is then embedded in a swellable hydrogel and expanded physically, allowing structures that are normally far below the resolution limit of conventional light microscopy to be seen.
The resulting images reveal the architecture of the immune synapse in actual human tumour tissue, rather than in cultured cell lines. Immunotherapy has dramatically altered the landscape of cancer treatment, yet patient responses remain highly variable. Some individuals experience durable tumour regression, while others show little or no benefit. The underlying reasons for this unpredictability have been elusive.
The new images provide a direct look at one possible factor: the composition and geometry of the cytotoxic granules that T cells deploy. The granules were observed to differ in the makeup of their internal cores, suggesting that not all T‑cell attacks are mechanically identical.
Beyond the granules, the dome itself appears to be a dynamic structure. Its shape and mechanical properties could influence how effectively the lethal payload is delivered. By mapping these features in three dimensions, scientists can begin to distinguish successful immune contacts from those that fail to kill the tumour cell.
While the study, published in *Cell Reports*, is still in an early stage and involves a limited number of patient samples, it demonstrates that cryo‑expansion microscopy can render invisible, sub‑nanometre details visible in real tissue. This contrasts with earlier approaches that often required harsher processing steps, potentially altering the native configuration of the cells.
The authors argue that this observational strategy flips the usual research paradigm. Rather than first identifying a therapeutic molecule and then trying to explain its action, they start by asking what a successful immune attack looks like at the molecular level, then work backward to uncover the mechanisms that enable it. Potential clinical implications are clear.
If the structural variations in the immune synapse can be linked to treatment outcomes, clinicians might one day predict which patients are likely to benefit from a given immunotherapy. Moreover, therapeutic designs could be refined to enhance the formation of the optimal dome geometry or to standardise the content of the cytotoxic granules, thereby increasing the probability of tumour eradication.
Although the method is still being refined and larger studies are needed to confirm the findings, the work provides a concrete visual “blueprint” of how T cells engage and kill cancer cells inside human tumours. By making the previously invisible visible, the Geneva‑CHUV/UNIL team has supplied the field of cancer immunology with a new tool for probing the mechanical basis of immune success and failure.
